SP33. Optimizing Patient Selection for Lympha in Patients with Inflammatory Breast Cancer

• Colby J. Hyland, AB,
• Libby R. Copeland-Halperin, MD,
• Goutam K. Gadiraju, BS,
• David Xiang, AB,
• Jennifer R. Bellon, MD,
• Filipa Lynce, MD,
• Tanujit Dey, PhD,
• Sean J. Ryan, MA, MS,
• Faina Nakhlis, MD, FACS,
• Justin M. Broyles, MD

Affiliations

Colby J. Hyland, AB

1 Harvard Medical School, Boston, MA, USA

Libby R. Copeland-Halperin, MD

2 Harvard Medical School; Brigham and Women’s Hospital, Boston, MA

Goutam K. Gadiraju, BS

1 Harvard Medical School, Boston, MA, USA

David Xiang, AB

1 Harvard Medical School, Boston, MA, USA

Jennifer R. Bellon, MD

3 Dana Farber Cancer Institute, Boston, MA, USA.

Filipa Lynce, MD

3 Dana Farber Cancer Institute, Boston, MA, USA.

Tanujit Dey, PhD

2 Harvard Medical School; Brigham and Women’s Hospital, Boston, MA

Sean J. Ryan, MA, MS

3 Dana Farber Cancer Institute, Boston, MA, USA.

Faina Nakhlis, MD, FACS

3 Dana Farber Cancer Institute, Boston, MA, USA.

Justin M. Broyles, MD

2 Harvard Medical School; Brigham and Women’s Hospital, Boston, MA